StockData
DexCom Inc logo

DexCom Inc (DXCM) stock

DXCMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 22/3031% below fair value
$82.04+0.43 (+0.53%)

Close on Nov 17, 2026Market cap $30.60BP/E 32.3Yield –

DexCom r&d expenses

Research and development expenses are spending on new products and technology.

DexCom's R&D Expenses for the twelve months ending Sep 30, 2026 was $608.10M, up 3.0% year over year. For fiscal 2025 it was $599.10M, up 8.5% from the year before. Over ten years it grew 15.9% a year on average. The highest annual figure on record is $599.10M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$599.10M+8.5%
FY2024Dec 31, 2024$552.40M+9.2%
FY2023Dec 31, 2023$505.80M+4.5%
FY2022Dec 31, 2022$484.20M-6.4%
FY2021Dec 31, 2021$517.10M+43.7%
FY2020Dec 31, 2020$359.90M+31.6%
FY2019Dec 31, 2019$273.50M+37.0%
FY2018Dec 31, 2018$199.70M+7.7%
FY2017Dec 31, 2017$185.40M+18.8%
FY2016Dec 31, 2016$156.10M+13.5%
FY2015Dec 31, 2015$137.50M+98.1%
FY2014Dec 31, 2014$69.40M+54.9%
FY2013Dec 31, 2013$44.80M+17.0%
FY2012Dec 31, 2012$38.30M+29.4%
FY2011Dec 31, 2011$29.60M+27.6%
FY2010Dec 31, 2010$23.20M+62.3%
FY2009Dec 31, 2009$14.29M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$161.60M+2.6%
Q2 FY2026Jun 30, 2026$153.00M+3.2%
Q1 FY2026Mar 31, 2026$145.30M+0.1%
Q4 FY2025Dec 31, 2025$148.20M+6.2%
Q3 FY2025Sep 30, 2025$157.50M+16.3%
Q2 FY2025Jun 30, 2025$148.20M+9.0%
Q1 FY2025Mar 31, 2025$145.20M+2.6%
Q4 FY2024Dec 31, 2024$139.50M+2.5%
Q3 FY2024Sep 30, 2024$135.40M+3.0%
Q2 FY2024Jun 30, 2024$136.00M+14.0%
Q1 FY2024Mar 31, 2024$141.50M+18.9%
Q4 FY2023Dec 31, 2023$136.10M+17.0%
Q3 FY2023Sep 30, 2023$131.40M+19.1%
Q2 FY2023Jun 30, 2023$119.30M-2.0%
Q1 FY2023Mar 31, 2023$119.00M-12.4%
Q4 FY2022Dec 31, 2022$116.30M-22.4%
Q3 FY2022Sep 30, 2022$110.30M-14.4%
Q2 FY2022Jun 30, 2022$121.70M-5.7%
Q1 FY2022Mar 31, 2022$135.90M+24.2%
Q4 FY2021Dec 31, 2021$149.80M+25.7%
Q3 FY2021Sep 30, 2021$128.80M+46.9%
Q2 FY2021Jun 30, 2021$129.10M+61.6%
Q1 FY2021Mar 31, 2021$109.40M+49.7%
Q4 FY2020Dec 31, 2020$119.20M+51.3%
Q3 FY2020Sep 30, 2020$87.70M+31.5%
Q2 FY2020Jun 30, 2020$79.90M+15.8%
Q1 FY2020Mar 31, 2020$73.10M+23.9%
Q4 FY2019Dec 31, 2019$78.80M+36.8%
Q3 FY2019Sep 30, 2019$66.70M+33.1%
Q2 FY2019Jun 30, 2019$69.00M+46.2%
Q1 FY2019Mar 31, 2019$59.00M+31.7%
Q4 FY2018Dec 31, 2018$57.60M+18.3%
Q3 FY2018Sep 30, 2018$50.10M+15.7%
Q2 FY2018Jun 30, 2018$47.20M+4.2%
Q1 FY2018Mar 31, 2018$44.80M-6.9%
Q4 FY2017Dec 31, 2017$48.70M+11.4%
Q3 FY2017Sep 30, 2017$43.30M–
Q2 FY2017Jun 30, 2017$45.30M–
Q1 FY2017Mar 31, 2017$48.10M–
Q4 FY2016Dec 31, 2016$43.70M–

More DexCom figures

See a number that looks wrong?